Drug Interactions : BPC-157's interaction with nitric oxide pathways and growth hormone receptors raises concerns about interference with medications (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), anticoagulants, and hormonal therapies)
At a glance Direct interaction data / none published in human trials as of May 2026 BPC-157 primary mechanism / nitric oxide system modulation, angiogenesis, and GI cytoprotection Ashwagandha primary mechanism / HPA-axis modulation, cortisol reduction, withanolide-driven adaptogenesis Overlap concern / both influence the hypothalamic-pituitary-adrenal and hypothalamic-pituitary-thyroid axes Suggested dose separation / 30 to 60 minutes between oral ashwagandha and oral BPC-157 Monitoring labs / TSH, free T4, morning cortisol at baseline and every 8 to 12 weeks Ashwagandha cortisol reduction / 30.5% decrease in serum cortisol vs
These cells, which accumulate with age, no longer divide but resist programmed cell death, contributing to inflammation and tissue dysfunction
The cautious approach for women in their 50s with a family history of hormone-sensitive cancers is to discuss the question with both the prescribing clinician and the womans oncologist or primary care provider before initiating any peptide that elevates IGF-1
